BOLT BIOTHERAP. DL-00001
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
BOLT BIOTHERAP. DL-00001 (6LP) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BOLT BIOTHERAP. DL-00001 (6LP) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BOLT BIOTHERAP. DL-00001 - Net Assets Trend (None–None)
This chart illustrates how BOLT BIOTHERAP. DL-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BOLT BIOTHERAP. DL-00001 (None–None)
The table below shows the annual net assets of BOLT BIOTHERAP. DL-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BOLT BIOTHERAP. DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BOLT BIOTHERAP. DL-00001 Competitors by Market Cap
The table below lists competitors of BOLT BIOTHERAP. DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PC CONNECTION
MU:PCC
|
$530.19K |
|
AMADEUS IT HOLD -A- - Dusseldorf Stock Exchang
DU:AI3A
|
$530.63K |
|
NOVOZYMES -B-
BE:NZM2
|
$530.78K |
|
ASA GOLD+PREC.MET.LTD.DL1
F:FZ6
|
$531.01K |
|
Gentor Resources Inc
PINK:GNTOF
|
$529.23K |
|
Evolution AB
STU:E3G1
|
$529.13K |
|
PURE EXTRACTS TECHN. CORP
F:PUX
|
$528.88K |
|
NORTHEAST UTILITIES
BE:NWJ
|
$528.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BOLT BIOTHERAP. DL-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BOLT BIOTHERAP. DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BOLT BIOTHERAP. DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BOLT BIOTHERAP. DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BOLT BIOTHERAP. DL-00001 (6LP) | €- | N/A | N/A | $529.61K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |